4DMT reports new phase 2b gene therapy data for wet AMD
4D Molecular Therapeutics reported positive 2-year results from its phase 2b PRISM trial of 4D-150 for wet age-related macular degeneration. The company said the study showed sustained BCVA and OCT central subfield thickness improvements and reduced treatment burden versus projected on-label aflibercept. Safety was described as well tolerated, with 2.8% mild transient inflammation. Phase 3 topline data is expected in 2027.
How this was made
The 30-second read
Why it matters
The new disclosure is a durability and treatment-burden update from the Phase 2b PRISM trial, plus a safety recap emphasizing low inflammation incidence and no reported serious ocular AEs to date.
Market read
Durability and reduced injection burden from 2-year Phase 2b data can shift expectations for wet AMD Phase 3, but the absence of Phase 3 results limits conviction.
What to watch
The article does not quantify visual acuity magnitude, durability failure rates, or long-term safety beyond the stated follow-up cutoff, which could temper enthusiasm.
Background
4D-150 is an intravitreal gene therapy using a dual transgene payload (aflibercept plus VEGF-C inhibitory RNAi) delivered via a customized synthetic AAV capsid-derived vector (R100).
Ticker impact
4D Molecular Therapeutics reported positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD, including treatment-burden reductions and safety follow-up.
Potential near-term positive bias for FDMT on clinical-data sentiment, with follow-through dependent on how investors weigh durability and safety versus Phase 3 expectations.
The article provides specific efficacy and safety datapoints (2-year durability, burden reduction, low inflammation incidence, no serious ocular AEs reported) but does not include Phase 3 results or new regulatory/financing catalysts.
Market effects
Supports the broader anti-VEGF delivery innovation theme (sustained, low-dose intravitreal gene therapy) within ophthalmology biotech.
Primarily US-listed biotech sentiment, with conference-driven read-through for global retina-focused investors.
Wet AMD remains a large global market; durable efficacy signals can influence international peers’ competitive positioning narratives.
Counterpoint
Investors may discount Phase 2b durability claims if Phase 3 endpoints, responder rates, or durability consistency fail to replicate in larger populations.
Key entities
- company4D Molecular Therapeutics
Sponsor of 4D-150 and developer of the Therapeutic Vector Evolution platform.
- product_candidate4D-150
Intravitreal gene therapy for wet AMD using aflibercept plus VEGF-C inhibitory RNAi.
- clinical_trialPRISM trial
Phase 1/2a and 2b study evaluating 4D-150 in wet AMD, with new 2-year data presented at ASRS 2026.
- clinical_trial4FRONT-1 and 4FRONT-2
Phase 3 wet AMD registrational trials; topline data expected in H1 2027 and H2 2027, respectively.
